EP Patent
EP3984528B1 — Pharmaceutical compositions comprising nilotinib
Assigned to Novartis AG · Expires 2023-07-05 · 3y expired
What this patent protects
Patent listed against nilotinib-hydrochloride.
Drugs covered by this patent
- nilotinib-hydrochloride (Nilotinib Hydrochloride) · Jan Beumer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.